Pharma Focus Asia

Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production for Cellular Medicines

Tuesday, July 23, 2019

Avalon GloboCare Corp., a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced that they have established a strategic partnership with GE Healthcare.  The partnership will accelerate Avalon’s standardization, automation and bio-production for clinical-grade Chimeric Antigen Receptor (CAR)-T cells and other immune-effector cells for cellular immunotherapy, as well as exosomes/extracellular vesicles (EV) based regenerative therapeutics.  The combination of expertise sets the stage for Avalon to be the leader in cellular medicines with the ability to execute on the complete development lifecycle from innovation through bio-production to the delivery and management of treatment at hospitals for patients.  This infrastructure and depth of capabilities ensures the successful execution of the company’s ongoing clinical trials.

Under this partnership, both Avalon and GE Healthcare will strategically establish automated and standardized GMP cell production capabilities.  Avalon will be given access to GE Healthcare’s cell processing expertise and products in the form of FlexFactory Cell Therapy platform, FastTrak process development and training services, as well as extensive SOP and validation protocol library.  Additionally, user training will be conducted both at GE Healthcare and on-site at Avalon’s Nanjing Epicon GMP facility with access to GE Healthcare’s expert bio-manufacturing resources.  In conjunction with Avalon’s extensive clinical network in China, this strategic partnership will empower Avalon to improve manufacturing throughput and efficiency, alleviate cost burden, and minimize variability in the automated and standardized bio-production process of clinical-grade cellular products (such as CAR-T, CAR-NK, and stem cell-derived exosomes/EV), therefore, accelerating the development of Avalon’s clinical and commercialization programs in cellular medicines.

“We are pleased to establish this strategic partnership with GE Healthcare.  This is a crucial and exciting time in the evolution of cellular medicines and our combined skills will drive Avalon to move innovation forward and ultimately deliver the best therapeutic solutions for patients.  This partnership enables Avalon to more fully leverage and integrate our core technology platforms and accelerate our clinical programs in cellular immunotherapy and stem cell-derived exosome-based regenerative therapeutics.  Empowered by GE’s leading automation and standardized cell processing/bio-production capabilities, we look forward to further upgrading our infrastructure, services and products, as well as expanding our leadership role in cellular medicines,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.

“Cellular medicines as a bio-industry sector has been growing and evolving at a rapid pace during recent years with vast potential to change the way various diseases are managed.  GE Healthcare continues investing in technologies and services aimed at the thriving cellular medicine industry with a firm commitment of making these promising cellular therapeutic modalities accessible through successful industrialization.  We are pleased to work with Avalon GloboCare, a global leader in cell-based therapeutics and exosome technology, who share our mission and vision for advancing innovation  and delivering automation, standardization and bio-production solutions for cellular medicines,” said Angela Chen, GE Healthcare CGT Global Commercial Enterprise Solution Leader.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024